DOCSLIB.ORG

Zicronapine (Schizophrenia) – Forecast and Market Analysis to 2022

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Zicronapine (Schizophrenia) – Forecast and Market Analysis to 2022 REFERENCE CODE GDHC368DFR | PUBLICATION DATE FEBRUARY 2014 ZICRONAPINE (SCHIZOPHRENIA) – FORECAST AND MARKET ANALYSIS TO 2022 ZICRONAPINE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Table below provides a summary of the key D1 and 5-HT2A-preferring mechanism may be metrics for Zicronapine in the seven major useful in treatment-resistant cases or patients pharmaceutical markets during the forecast period displaying suicidal behavior. upto 2022. Conversely, the major barriers for the growth of Zicronapine : Key Metrics in the Seven Major Zicronapine in the schizophrenia market include: Pharmaceutical Markets, 2012–2022 Key Events (2012-2022) Level of Impact Does not target a current unmet need. Anticipated launch of Zicronapine in US ↑↑ Must display efficacy over the market’s most- (2017) Anticipated launch of Zicronapine in effective therapies (Zyprexa and Clozaril). ↑↑↑ Japan (2018) The figure below illustrates Zicronapine sales in 2022 Market Sales US $164.0 m the 7MM by region during the forecast period. 5EU $11.2m Sales for Zicronapine by Region, 2022 Japan $76.3m 7MM $251.5m 2022 Source: GlobalData. 30.3% Total : $251.5m 7MM = US, France, Germany, Italy, Spain, UK, Japan; 5EU = France, Germany, Italy, Spain, UK US Sales for Zicronapine in Global Schizophrenia 5EU Market, 2022 4.5% 65.2% Japan Zicronapine sales are expected to increase from $16.8 million upon its launch in 2017 to $251.5 Source: GlobalData. million in 2022. Major growth drivers for Zicronapine in the schizophrenia market over the forecast period include: Less-frequent dosing than clozapine, which shares a similar preference for D1 dopamine receptors. Not associated with treatment-emergent agranulocytosis like clozapine. Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022 2 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form. ZICRONAPINE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary What Do the Physicians Think? in terms of epidemiology. But they have increased in terms of rate of prescribing because the “Unfortunately there is really nothing out there diagnosis has expanded to which these which would give me confidence that we will have medications are directed to.” something reasonably effective in the next several years. We are probably coming to one set of [EU] KOL, November 2013 results very soon, probably sometime early next “[We] treat them according to the presenting year or maybe the spring of next year, the syndrome. And even more specifically – in terms of glutamatergic compounds.” the positive symptoms, depression, affective [US] KOL, October 2013 symptoms, or cognitive symptoms, negative symptoms – they will be cueing in much more on “There isn’t that much coming out these days, so that rather than on the label of, ‘Is this that’s a fact which many of us have actually agreed schizoaffective, is it bipolar, is it a schizophrenic on is a major, major issue. We’ve had discussions patient?’ I think once it gets down to medications, with pharmaceutical companies as a group of then it gets much simpler. These discussions do pharmacologically oriented and research-oriented not reach into the medication decision-making psychiatrists and say, ‘Please come back and process.” reactivate your research and development sections and divisions. Don’t desert this group of patients, [EU] KOL, December 2013 because we need better drugs.’ There’s no doubt “Going systematically, you have the glutamatergic about it.” compounds, you have nicotinic acid agonists, you [US] KOL, September 2013 have the me-too drugs, which are the D2/5-HT2 antagonists, and of those we have plenty, we don’t “If you look at the utilization patterns of need anything more, that mechanism of action is antipsychotics you do see that once the atypicals entirely taken care of, so to speak.” were introduced, the usage of these medications went up significantly. And this is not at all because [US] KOL October, 2013 there are more schizophrenic patients around. In fact, schizophrenia has actually decreased slightly Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022 3 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form. ZICRONAPINE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Table of Contents 1 Table of Contents 1 Table of Contents .......................................................................................................................... 4 1.1 List of Tables ........................................................................................................................ 7 1.2 List of Figures ....................................................................................................................... 7 2 Introduction ................................................................................................................................... 8 2.1 Catalyst ................................................................................................................................. 8 2.2 Related Reports .................................................................................................................... 9 2.3 Upcoming Reports .............................................................................................................. 10 3 Disease Overview ....................................................................................................................... 11 3.1 Etiology and Pathophysiology ............................................................................................. 11 3.1.1 Etiology ........................................................................................................................... 11 3.1.2 Pathophysiology ............................................................................................................. 12 3.2 Symptoms ........................................................................................................................... 13 4 Disease Management.................................................................................................................. 14 4.1 Diagnosis ............................................................................................................................ 14 4.1.1 Subjective Assessments ................................................................................................. 15 4.1.2 Disease Subtypes ........................................................................................................... 16 4.2 Treatment Overview ............................................................................................................ 18 4.2.1 Treatment of Acute Agitation Associated with Schizophrenia .......................................... 21 4.2.2 Maintenance Treatment of Schizophrenia ....................................................................... 22 5 Competitive Assessment ............................................................................................................. 23 5.1 Overview ............................................................................................................................. 23 Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022 4 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form. ZICRONAPINE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Table of Contents 5.2 Strategic Competitor Assessment ....................................................................................... 24 6 Opportunity and Unmet Need ...................................................................................................... 26 6.1 Unmet Needs Overview ...................................................................................................... 26 6.1.1 Public Awareness ........................................................................................................... 27 6.1.2 Early Diagnosis and Treatment ....................................................................................... 29 6.1.3 Long-Acting and Advanced Drug Delivery Systems ........................................................ 30 6.1.4 Effective Management of Negative and Cognitive Symptom Domains ............................ 31 6.2 Gap Analysis ....................................................................................................................... 32 6.2.1 Long-Acting Drug Delivery .............................................................................................. 33 6.2.2 Treatment of Negative and Cognitive Symptoms ............................................................ 33 7 Pipeline Assessment ................................................................................................................... 34 7.1 Overview ............................................................................................................................. 34 7.2 Early-Stage Pipeline Assessment ....................................................................................... 34 7.3 Novel Therapeutic Approaches ........................................................................................... 35 7.3.1 Negative Symptoms ........................................................................................................ 36 7.3.2 Cognitive Symptoms ......................................................................................................
Load more

Recommended publications
  • (Schizophrenia) – Forecast and Market Analysis to 2022
    REFERENCE CODE GDHC367DFR | PUBLICATION DATE FEBRUARY 2014 BREXPIPRAZOLE (SCHIZOPHRENIA) – FORECAST AND MARKET ANALYSIS TO 2022 BREXPIPRAZOLE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Table below provides a summary of the key May have an effect on negative symptoms. metrics for Brexpiprazole in the seven major Otsuka has a strong presence in the pharmaceutical markets during the forecast period schizophrenia drug market. upto 2022. Conversely, the major barriers for the growth of Brexpiprazole : Key Metrics in the Seven Major Brexpiprazole in the schizophrenia market include: Pharmaceutical Markets, 2012–2022 Key Events (2012-2022) Level of Impact Higher cost of therapy compared to older Anticipated launch of Brexpiprazole in ↑↑↑ medications. US(2015) Anticipated launch of Brexpiprazole in ↑↑ Requires daily oral dosing. Japan (2016) 2022 Market Sales The figure below illustrates Brexpiprazole sales in US $1,648.9m the 7MM by region during the forecast period. 5EU $28.4m Japan $105.8m Sales for Brexpiprazole by Region, 2022 7MM $1,783.1m 5.9% 1.6% 2022 Source: GlobalData. Total : $1,783.1m 7MM = US, France, Germany, Italy, Spain, UK, Japan; 5EU = France, Germany, Italy, Spain, UK US Sales of Brexpiprazole in Global Schizophrenia 5EU Market, 2022 Japan Brexpiprazole sales are expected to increase from $176.2 million upon launch in 2015 to $1,783.1 92.5% million in 2022. Source: GlobalData. Major growth drivers for Brexpiprazole in the Schizophrenia market over the forecast period include: Structurally similar to Otsuka’s Abilify, the current market leader in the schizophrenia drug market. Improved tolerability and similar efficacy to Abilify demonstrated in clinical trials.
    [Show full text]
  • FDA Provides New Guidance on Antipsychotic Usage During
    Clinical News Peter F. Buckley, MD Editor-in-Chief FDA Provides New Guidance on impact of prolonged exposure to antipsychotic medications Antipsychotic Usage during upon total brain volume, as well as both gray matter and Pregnancy caudate-putamen volumes. Modest volumetric reductions were observed. There appeared to be a dose effect of antipsy- The U.S. Food and Drug Administration (FDA), tak- chotics as well. Although the effects were not independent ing stock of all available and new pharmacoepidemiological of other factors that are known to influence potential brain information on antipsychotic medication use, has provided changes—namely, duration of follow-up, illness severity, and updated guidance on prescribing antipsychotics during and comorbid substance abuse—the effect of medications per- immediately after pregnancy. Firstly, the FDA report affirms sisted even when these other influences were taken into ac- the long-held clinical message that untreated psychosis in count statistically. This is a noteworthy observation. the expectant mother is associated with (far) greater risk While the results are still open to other interpretations, than the risks associated with continued use of antipsychot- the observations for this study are sobering. They are also ics. Nevertheless, the report cautions about risks of antipsy- in line with earlier preclinical studies from the University chotic medications for extrapyramidal side effects (EPS) and of Pittsburgh that have demonstrated potential neurotoxic withdrawal side effects in the newborn. The report cites out- effects of antipsychotic medication upon selective neurons. comes for 69 instances of EPS and withdrawal side effects Nevertheless, the “jury is still out” on this contentious top- that were reported to the FDA up until the fall of 2008.
    [Show full text]
  • WO 2016/123576 Al 4 August 2016 (04.08.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/123576 Al 4 August 2016 (04.08.2016) P O P C T (51) International Patent Classification: Unit L, Baltimore, Maryland 21209 (US). WEINBER¬ A61K 31/535 (2006.01) GER, Daniel; 3116 Davenport St. NW, Washington, Dis trict of Columbia 20008-2244 (US). (21) International Application Number: PCT/US2016/015832 (74) Agent: KELLY, Bryte; King & Spalding LLP, 1185 Av enue of the Americas, New York, New York 10036 (US). (22) International Filing Date: 29 January 2016 (29.01 .2016) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Language: English Filing AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 62/109,954 30 January 2015 (30.01.2015) US KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant: LIEBER INSTITUTE FOR BRAIN DE¬ MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, VELOPMENT [US/US]; 855 North Wolfe Street, Suite PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 300, 3rd Floor, Baltimore, Maryland 21205 (US). SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Davey KJ Phd 2013.Pdf
    UCC Library and UCC researchers have made this item openly available. Please let us know how this has helped you. Thanks! Title The gut microbiota as a contributing factor to antipsychotic-induced weight gain and metabolic dysfunction Author(s) Davey, Kieran Publication date 2013 Original citation Davey, K. 2013. The gut microbiota as a contributing factor to antipsychotic-induced weight gain and metabolic dysfunction. PhD Thesis, University College Cork. Type of publication Doctoral thesis Rights © 2013. Kieran Davey http://creativecommons.org/licenses/by-nc-nd/3.0/ Embargo information Restricted to everyone for one year Item downloaded http://hdl.handle.net/10468/1243 from Downloaded on 2021-10-09T20:00:22Z Ollscoil na hEireann National Unversity Ireland Colaiste na hOllscoile, Corcaigh University College Cork School of Pharmacy The Gut Microbiota as a Contributing Factor to Antipsychotic-Induced Weight Gain and Metabolic Dysfunction Thesis presented by Kieran J. Davey under the supervision of Prof. John F. Cryan Prof. Timothy G. Dinan Dr Siobhain M. O’Mahony for the degree of Doctor of Philosophy Head of School: CatrionaO’Driscoll Contents Declaration ........................................................................................................................................... vii Acknowledgements .......................................................................................................................... viii Publications and presentations .....................................................................................................
    [Show full text]
  • Achat Viagra Puissant ### Ablation Prostate Et Viagra >>> Kvadridze.Github.Io
    Viagra est indiquée pour le traitement de la dysfonction érectile masculine. >>> ORDER NOW <<< Achat viagra puissant Tags: ordonnance de viagra combien de temps dur viagra comment peut on se procurer du viagra efficacité viagra générique un site fiable pour acheter du viagra le viagra sur ordonnance danger dacheter du viagra sur internet prix cachet viagra combien coute le viagra au maroc le rôle de viagra peut acheter du viagra sans ordonnance quesque cest viagra composition de viagra acheter viagra paris sans ordonnance comment se procurer viagra sans ordonnance comment reconnaitre le faux viagra quand faut il prendre viagra comment acheter du viagra au quebec lancement du viagra quest ce que cest le viagra viagra pfizer mode demploi les conséquences du viagra edex plus viagra comment prendre de viagra forum viagra pas cher commande de viagra en ligne meme effet que viagra prendre la moitié dun viagra experience viagra femme A vaginal ring can slip out of the vagina. In the event of overdosage, general symptomatic and achat viagra puissant measures are indicated as required Resistance to azithromycin may be inherent or acquired. Comments: Take one pill a day. Ca 20 minuter senare börjar mina kollegor droppa in i ordningen: Susanne, Britt, Emma, Nina, Gunnel, Eva och sist Barbro. Epidemiologic investigations of this outbreak demonstrated that individuals in close contact with the index case or with exposure to poultry were at risk of being infected. 25 mg pour femme viagra cherche 2 weeks or until I "felt" like I could go lower. It might take a while to adapt to it, since it will lower your blood pressure.
    [Show full text]
  • Terminology Drug Development
    P. de Boer 20-3-2013 Drug Development 1. Drug development is for a well-accepted and New Developments in the demarcated indication that will become part Pharmacological Therapy of of the product label (rather than for a symptom – family of symptoms); Schizophrenia 2. Symptoms may overlap between disease Peter de Boer, PhD categories. It is acceptable to develop Senior Director Experimental Medicine multiple indications but it is generally not Janssen Research and Development acceptable to develop symptom-specific therapies. 3/8/2013 Psychosis Cluster 4 This presentation may contain off-label information or data on investigational compounds. Please always refer to the full product information before prescribing any medicine. Section 1 Views and opinions expressed in this presentation represent those of the presenter and are not necessarily the company. WHY CATEGORIES RATHER THAN DIMENSIONS? 3/8/2013 Psychosis Cluster 2 3/8/2013 Psychosis Cluster 5 Schizophrenia as a disorder of Terminology Frequency cognition (1) Category: An ICD-10/DSM-IV diagnosis (e.g., • Schizophrenia Normal schizophrenia, schizoaffective disorder, Morbid schizotypal personality disorder); Premorbid • Dimension: A symptom or symptom cluster that occurs throughout the population and that, if of sufficient intensity, may lead to a categorical diagnosis (e.g., aberrant sensory experiences); • Symptom: A characteristic sign (e.g., a delusion, IQ Test Score avolition); Impaired Normal High Functioning • Target: A biological process affected by a drug. 3/8/2013 Psychosis Cluster 3 3/8/2013 Psychosis Cluster 6 Nascholing Psychosen 14-15 maart 2013 1 P. de Boer 20-3-2013 Schizophrenia as a disorder of Psychosis: Dimension/Category (2) Frequency cognition (2) Intensity Schizophrenia Psychotic Experiences Schizophrenia Normal 1% Schizotypical Tx A 10% C Normal 1% Test Score 40% 49% Impaired B Normal High Functioning Not strictly continuous variables? 3/8/2013 Psychosis Cluster 7 3/8/2013 Psychosis Cluster 10 Schizophrenia as a disorder of Psychosis in dementia cognition - issues 1.
    [Show full text]
  • Current Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE
    Send Orders for Reprints to [email protected] 3385 Cur rent Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE ISSN: 1568-0266 eISSN: 1873-5294 Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Impact Factor: 2.9 The international Present and Future journal for in-depth reviews on Current Topics in Medicinal Chemistry BENTHAM SCIENCE Peng Li*, Gretchen L. Snyder and Kimberly E. Vanover Intra-Cellular Therapies Inc, 430 East 29th Street, Suite 900, New York, NY 10016, USA Abstract: Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approxi- mately 1% of the world’s population. This disease is associated with considerable morbidity placing a major financial burden on society. Antipsychotics have been the mainstay of the pharmacological treatment of schizophrenia for decades. The traditional typical and atypical antipsychotics demon- strate clinical efficacy in treating positive symptoms, such as hallucinations and delusions, while are A R T I C L E H I S T O R Y largely ineffective and may worsen negative symptoms, such as blunted affect and social withdrawal, as well as cognitive function. The inability to treat these latter symptoms may contribute to social Received: April 07, 2016 Revised: May 20, 2016 function impairment associated with schizophrenia. The dysfunction of multiple neurotransmitter Accepted: May 23, 2016 systems in schizophrenia suggests that drugs selectively targeting one neurotransmission pathway DOI: 10.2174/1568026616666160608 are unlikely to meet all the therapeutic needs of this heterogeneous disorder. Often, however, the un- 084834 intentional engagement of multiple pharmacological targets or even the excessive engagement of in- tended pharmacological targets can lead to undesired consequences and poor tolerability.
    [Show full text]
  • Annual Report 2011 3) the Calculation Is Based on a Share Denomination of DKK 5
    Financial highlights Group 2011 2010 2009 2008 2007 2011 2011 DKKm DKKm DKKm DKKm DKKm EURm1 USDm2 Revenue 16,007 14,765 13,747 11,572 11,171 2,148 2,987 Research and development costs 3,320 3,045 3,196 2,990 2,193 446 620 Operating profit before depreciation and amortisation (EBITDA) 4,628 4,393 3,728 3,418 3,611 621 864 Profit from operations (EBIT) 3,393 3,357 2,858 2,354 2,689 455 633 Net financials (96) (68) (192) (28) 65 (13) (18) Profit for the year 2,282 2,466 2,007 1,663 1,881 306 426 Total assets 20,534 18,005 17,127 12,526 12,230 2,762 3,574 Equity 12,776 11,122 8,803 7,511 7,089 1,719 2,224 Cash flows from operating and investing activities 929 2,462 (2,040) 2,193 1,610 125 173 Investments in property, plant and equipment, gross 419 383 258 229 474 56 73 % % % % % % % EBITDA margin 28.9 29.8 27.1 29.5 32.3 28.9 28.9 EBIT margin 21.2 22.7 20.8 20.3 24.1 21.2 21.2 Return on capital employed 25.3 27.6 28.0 30.0 34.6 25.3 25.3 Return on equity 19.1 24.8 24.6 22.8 27.3 19.1 19.1 Research and development ratio 20.7 20.6 23.2 25.8 19.6 20.7 20.7 Solvency ratio 62.2 61.8 51.4 60.0 58.0 62.2 62.2 Capital turnover 78.0 82.0 80.3 92.4 91.3 78.0 78.0 Effective tax rate 30.8 25.0 24.7 27.1 29.6 30.8 30.8 DKK DKK DKK DKK DKK EUR1 USD2 Earnings per share (EPS)3 11.63 12.57 10.24 8.45 9.18 1.56 2.17 Diluted earnings per share (DEPS)3 11.63 12.57 10.24 8.45 9.17 1.56 2.17 Proposed dividend per share3 3.49 3.77 3.07 2.30 2.56 0.47 0.65 Cash flow per share3 18.48 16.65 15.47 14.12 13.18 2.48 3.45 Net asset value per share3 65.14 56.71 44.89
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients
    This is a repository copy of Antipsychotics for treatment of delirium in hospitalised non-ICU patients. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/132847/ Version: Published Version Article: Burry, Lisa, Mehta, S.R., Perreault, M.M et al. (6 more authors) (2018) Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews. CD005594. ISSN 1469-493X https://doi.org/10.1002/14651858.CD005594.pub3 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Antipsychotics for treatment of delirium in hospitalised non- ICU patients (Review) Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews 2018, Issue 6.
    [Show full text]
  • Global Drug Forecast and Market Analysis to 2022
    REFERENCE CODE GDHC81PIDR | PUBLICATION DATE FEBRUARY 2014 SCHIZOPHRENIA – GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 SCHIZOPHRENIA - GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Schizophrenia: Key Metrics in the Seven Major The table above provides a summary of the key Pharmaceutical Markets, 2012–2022 metrics for schizophrenia in the seven major 2012 Epidemiology pharmaceutical markets during the forecast period Prevalent population 2.5 million from 2012–2022. Treated population 2.0 million 2012 Market Sales Schizophrenia Drug Sales by Region, 2012– US $5.2bn 2022 5EU $0.4bn Japan $0.7bn The combined sales of medications carrying an Total $6.3bn indication in schizophrenia were estimated at $6.3 Pipeline Assessment billion in 2012. By 2022, GlobalData projects these Number of drugs in Phase II–III 11 sales to grow to $7.9 billion, with a compound Number of first-in-class drugs 2 annual growth rate (CAGR) of 2.40% over the Peak-Year Promising Pipeline Candidates Sales course of the decade. These estimates cover the Brexpiprazole (Otsuka/Lundbeck) $1.8bn sales in the seven major markets (7MM) included Cariprazine (Forest/Gedeon Richter) $0.9bn in this report: the US, France, Germany, Italy, EVP-6124 (EnVivo/Mitsubishi Tanabe) $0.8bn Aripiprazole lauroxil (Alkermes) $0.7bn Spain, the UK, and Japan. We believe that the Invega Sustenna (Three-Month) $0.6bn following parameters will drive expansion in these Level of Key Events (2012–2022) markets: Impact Zyprexa (olanzapine) patent expiry in the ↓↓ Growing awareness of mental health 5EU in 2012 Seroquel (quetiapine) patent expiry in the US ↓↓ Enhanced community-level mental health care and 5EU in 2012 Geodon (ziprasidone) patent expiry in the US ↓ New product launches in 2012 Launch of Abilify Maintena (aripiprazole) in ↑↑↑ Increasing utilization of long-acting injectable the US in 2013 Abilify (aripiprazole) patent expiry in the US (LAI) antipsychotics ↓↓↓ and 5EU in 2015 2022 Market Sales US $6.1bn 5EU $0.4bn Japan $1.4bn 7MM $7.9bn Source: GlobalData.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]